Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT06345066·Phase 1·INTERVENTIONAL

A Study of LY3841136 in Overweight and Obese Participants

EloralintideWeight lossCompleted

Status

Completed

Phase

Phase 1

Enrollment

96

Locations

3

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

Interventions

Treatment arms and agents.

DRUG

Tirzepatide

Administered SC.

DRUG

LY3841136

Administered SC.

DRUG

Placebo

Administered SC.

Timeline

From registration to results.

  1. First posted

    Apr 3, 2024

  2. Study start

    Apr 3, 2024

  3. Primary completion

    Sep 29, 2025

  4. Study completion

    Sep 29, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Oct 15, 2025

Outcomes

What the study measures.

Primary outcomes

Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

Time frame · Baseline up to 42 weeks

A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

Secondary outcomes

Percent change from baseline in body weight

Time frame · Baseline, Week 42

Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3841136

Time frame · Predose up to 42 weeks

Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of LY3841136

Time frame · Predose up to 42 weeks

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
65 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation * Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²). * Have clinical laboratory test results within normal reference range * Have venous access sufficient to allow for blood sampling * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures Exclusion Criteria: * Have type 1 or type 2 diabetes mellitus * Have an abnormal 12-lead electrocardiogram (ECG) * Have a history or presence of psychiatric disorders * Have abnormal blood pressure and pulse rate * Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.

Study locations

3 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Fortrea Clinical Research Unit

Madison, Wisconsin, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Eloralintide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsEloralintide trial dashboard →